Statins in skin: Research and rediscovery, from psoriasis to sclerosis

Journal of Drugs in Dermatology

Volumn 9, Issue 8, 2010, Pages 921-927

  Egesi, Adaeze ^a   Sun, Grace ^a   Khachemoune, Amor ^b   Rashid, Rashid M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; TUMOR NECROSIS FACTOR ALPHA; DERMATOLOGICAL AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALOPECIA; ANGIOGENESIS; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHEMOTHERAPY; DERMATOLOGY; DRUG EFFECT; DRUG RESEARCH; HISTORY OF MEDICINE; HUMAN; IMMUNOREGULATION; LYMPHOCYTE MIGRATION; MAST CELL DEGRANULATION; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; PSORIASIS; RAYNAUD PHENOMENON; RECURRENT CANCER; SCLERODERMA; SCLEROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; TH1 TH2 BALANCE; ULTRAVIOLET A RADIATION; UPREGULATION; URTICARIA; ANIMAL; APOPTOSIS; PATHOPHYSIOLOGY; REVIEW; SKIN DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; DERMATOLOGIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SKIN DISEASES;

EID: 77955883787     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203(2):401-412. (Pubitemid 43290849)
2. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692. (Pubitemid 32588024)
3. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-1402. (Pubitemid 32001026)
4. Krauth MT, Majlesi Y, Sonneck K, et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy. 2006;61(3):281-288. (Pubitemid 43381804)
5. Zhang X, Markovic-Plese S. Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res. 2008;41(3):165-174.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33 (11):1569-1582.
7. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
8. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78-84. (Pubitemid 35291443)
9. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005;19(7):804-806. (Pubitemid 40617390)
10. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006;36(11):2885-2893. (Pubitemid 44782562)
11. Huang KC, Chen CW, Chen JC, Lin WW. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 2003;555(2):385-389.
12. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170(3):1524-1530. (Pubitemid 36139524)
13. Kanda H, Yokota K, Kohno C, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007;17(5):364-368. (Pubitemid 47593482)
14. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733-4741.
15. Freyschmidt-Paul P, McElwee KJ, Hoffmann R, et al. Interferon-gamma- deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515-521. (Pubitemid 44215480)
16. Robins DN. Case reports: Alopecia universalis: Hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol. 2007;6(9):946-947.
17. Lawman S, Mauri C, Jury EC, et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173(12):7641-7646. (Pubitemid 39628206)
18. Nickoloff BJ, Griffiths CE. Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. J Invest Dermatol. 1991;96(5):91S-92S.
19. Van den Wigngaard R, Wankowicz-Kaliknska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000;80(8):1299-1309. (Pubitemid 30637070)
20. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new therapeutic target in inflammatory dermatoses. J Dermatolog Treat. 2008:1-9.
21. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13:711-718. (Pubitemid 46889754)
22. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461-467. (Pubitemid 350305203)
23. Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-2630.
24. Doherty SD, Ni X, Doherty CB, et al. Abnormal expression of interleukin- 23 in mycosis fungoides/Sézary syndrome lesions. Arch Dermatol Res. 2006;298(7):353-356.
25. Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res. 2008;14(3):646-653. (Pubitemid 351231143)
26. Dos Santos JC, Azor MH, Nojima VY, et al. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. Int Immunopharmacol. 2008;8(10):1433-1440.
27. Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allergy Immunol. 2007;33(1-2):144-155. (Pubitemid 351514140)
28. Schmidt WM, Spiel AO, Jilma B, et al. In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008;18(2):109-120.
29. Qiao J, Kontoyiannis DP, Wan Z, et al. Antifungal activity of statins against Aspergillus species. Med Mycol. 2007;45(7):589-593. (Pubitemid 350176708)
30. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis. 2008;60(4):369-373. (Pubitemid 351380767)
31. Bitto A, Minutoli L, Altavilla D, et al. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Pharmacol Res. 2008;57(2):159-169.
32. Abou-Raya A, Abou-Raya S, Helmii M. Statins: Potentially useful in therapy of systemic sclerosis-related raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35(9):1801-1808.
33. A Randomized Double-Blind, Open Label, Dose Comparison, Parallel Assignment, Efficacy Phase II Clinical Trial of Improving Diabetic Foot Ulcers With Atorvastatin. http://clinicaltrials.gov. NCT00134550.
34. Koomen ER, Joosse A, Herings RMC, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Euro J Cancer. 2007;43(17):2580-2589. (Pubitemid 350086942)
35. Sarrabayrouse G, Synaeve C, Leveque K, et al. Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia. 2007;9(12):1078-1090. (Pubitemid 350255356)
36. Clark E, Golub T, Lander E, Hynes R. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406(6795):532-535. (Pubitemid 30625739)
37. Glynn S, O'Sullivan D, Eustace A, et al. The 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer. 2008;8:9.
38. Tang JY, So PL, Epstein EH Jr. Novel hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224(3):257-264. (Pubitemid 47575674)
39. Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: A systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17-24.
40. Peramiquel L, Serra E, Dalmau J, et al. Occupational contact dermatitis from simvastatin. Contact Derm. 2005;52(5):286-287. (Pubitemid 40756571)
41. Anliker MD, Wüthrich B. Chronic urticaria to atorvastatin. Allergy. 2002;57(4):366. (Pubitemid 34280668)
42. König C, Eickert A, Scharfetter-Kochanek K, et al. Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol. 2001;44(4):689-692. (Pubitemid 32249533)
43. Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol. 2006;47(1):57-59.